Shanghai Junshi Biosciences Co., Ltd. SHJBF
3.35 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
3.08 Day range 3.08
2.99 52-week range 4.23
- YTD
- +8.77%
- 1 year
- -20.80%
- Market cap
- 3.44B
- EPS (ttm)
- -0.12
- YTD return
- +8.77%
- 1-year return
- -20.80%
- Volume
- 100
- Open
- 3.08
- Previous close
- 3.35
- Day's range
- 3.08 – 3.08
- 52-week range
- 2.99 – 4.23
2Y +2.11 (+170.16%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 27, 2026 | Mar 31, 2026 | — | -0.0029 | — | — |
| Feb 27, 2026 | Dec 31, 2025 | — | -0.0386 | — | — |
| Oct 28, 2025 | Sep 30, 2025 | — | -0.02528 | — | — |
| Aug 26, 2025 | Jun 30, 2025 | — | -0.0251 | — | — |
| Apr 25, 2025 | Mar 31, 2025 | — | -0.03306 | — | — |
News
Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF) Stock Short Interest Declines 80.0% 
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC 
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC 
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026 
Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates 
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications 
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor) 
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb) 
Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC 
Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
Your note
Sign in to keep a note on SHJBF — it syncs with the Stock Master app.